Monte Rosa Therapeutics(GLUE) - 2023 Q3 - Quarterly Report
Monte Rosa Therapeutics(GLUE)2023-11-10 05:04
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 For the transition period from ____________ to ____________ Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc. (Exact name of registrant as specified in its charter) | | | (State or other jurisdiction of incorporation or organization) 321 Harrison Avenue, Suite 900 Bo ...